A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features

Shigeta Moriya, Shigeo Ohba, Kazuhide Adachi, Yuya Nishiyama, Takuro Hayashi, Shinya Nagahisa, Takafumi Kaito, Shunsuke Nakae, Yuichi Hirose

研究成果: Article

3 引用 (Scopus)

抜粋

Brainstem glioma is impossible to resect completely, and patients with this type of glioma show a poor prognosis. Therefore, a more effective adjuvant therapy is required to prolong survival. Bevacizumab is an endothelial growth factor monoclonal antibody with strong anti-vascular effects, which may suppress tumor progression. We performed a retrospective study of data from 6 patients with brainstem glioma showing malignant features who were treated with bevacizumab. Tumor-associated lesions, as evaluated by T2 weighted or fluid-attenuated inversion-recovery magnetic resonance imaging, were reduced in all patients, although the timing of the start of bevacizumab administration and pretreatment were not uniform. Clinical symptoms improved in 4 patients and progression was inhibited in 2 patients. The Karnofsky performance status improved from 56.7 to 71.7 on average. The median reduction ratio of tumor-associated lesions was 76.3%, but tumor suppression did not last in any of the cases. Furthermore, 5 patients died of tumor progression, and 1 patient died of a complication of necrotizing colitis. The median progression-free survival after bevacizumab administration was 7 months. The median overall survival after diagnosis was 16.5 months. Bevacizumab might be a potential therapeutic option for progressive brainstem gliomas with malignant features.

元の言語English
ページ(範囲)228-233
ページ数6
ジャーナルJournal of Clinical Neuroscience
47
DOI
出版物ステータスPublished - 01-2018

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

これを引用